New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
12:09 EDTSNX, ETFC, MYL, HALO, PBPB, AMTD, GRUBOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday despite the government reporting that employers added 192K jobs in March and hired more in January and February than previously thought. The Nasdaq, which has been leading the equity indexes higher since the beginning of the year, is today's leader to the downside. While the Dow and S&P were down fractionally near noon, the Nasdaq was down about 2%. ECONOMIC EVENTS: In the U.S., the Department of Labor's monthly jobs report showed nonfarm payrolls increased 192K in March, versus the consensus forecast for 200K job additions. Notably, February's job gain was revised up to 197K from the prior estimate of 175K and January war revised up to 144K from 129K. The unemployment rate in March was steady at 6.7%. COMPANY NEWS: Shares of drugmaker Mylan (MYL) were up by a double-digit percentage in pre-market trading following a Financial Times report of the company's desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. Despite the rejection, Mylan shares remained up about 4% near midday... Four new stocks made their debuts on the New York Stock Exchange and Nasdaq this morning, highlighted by the initial public offering of food delivery service GrubHub (GRUB). GrubHub, which had priced its offering of 7.41M shares at $26.00, opened for trade at $40.00 per share. MAJOR MOVERS: Among the notable gainers was SYNNEX (SNX), which rallied 22% after the company’s first quarter results and second quarter outlook topped analysts’ consensus estimates. Also higher were shares of sandwich shop owner Potbelly (PBPB), which rose almost 6% after its stock was upgraded to Outperform at William Blair. Among the noteworthy losers was Halozyme (HALO), which dropped 29% after an independent committee recommended it temporarily halt patient enrollment and dosing of a Phase 2 trial evaluating a drug in patients with pancreatic cancer. Also lower for a second straight day were shares of brokerage firms E-Trade (ETFC) and TD Ameritrade (AMTD) amid concerns that regulators will look to eliminate one of the companies' more profitable businesses amid a growing furor over high-frequency trading sparked by Michael Lewis' new book "Flash Boys." INDEXES: Near midday, the Dow was down 34.07, or 0.21%, to 16,538.48, the Nasdaq was down 85.13, or 2.01%, to 4,152.61, and the S&P 500 was down 9.66, or 0.51%, to 1,879.11.
News For MYL;GRUB;PBPB;ETFC;AMTD;HALO;SNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTMYLJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
06:11 EDTMYLTeva takes 1.35% stake in Mylan, says 'ready to meet' on deal
Subscribe for More Information
May 27, 2015
12:10 EDTMYLTeva to sweeten offer for Mylan before July shareholder vote, NY Post says
Subscribe for More Information
08:33 EDTHALOHalozyme and Ventana enter into global agreement to develop companion diagnostic
Halozyme (HALO) and Ventana Medical Systems, a member of the Roche (RHHBY), announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan. HA is a glycosaminoglycan that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic, under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. The financial terms of the agreement were not disclosed.
May 26, 2015
07:10 EDTPBPBPotbelly Q2 same-store sales estimate raised at William Blair
Subscribe for More Information
May 25, 2015
13:56 EDTMYLMylan responds to claims of EPS forecasting by Perrigo
Mylan (MYL) announced that it was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish takeover rules, relating to its firm intention to make an offer to acquire Perrigo (PRGO). The clarification and retraction relates to certain forward-looking statements made by Mylan specifically during the "pendency of the offer" period concerning its long-stated target since 2012 of at least $6.00 in adjusted EPS by 2018. Subsequent to Mylan's May 5 earnings release, Perrigo submitted a complaint to the Irish Takeover Panel alleging that the reference to Mylan's $6.00 long-term target should be treated as a forward-looking profit forecast statement. Although Mylan's adjusted EPS goal has been a stated long-term target, and not a forecast of Mylan, at least during the offer period as it pertains to the Perrigo transaction, Mylan will no longer refer to that 2018 target or any other forward looking statements beyond 2015 that could constitute profit forecasts.
May 19, 2015
07:13 EDTAMTDBarclays to hold a conference
Subscribe for More Information
06:08 EDTMYLPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
19:01 EDTGRUBGrubHub CEO sees opportunity in nonrestaurant orders, WSJ says
Subscribe for More Information
12:07 EDTMYLPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
07:22 EDTMYLUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
13:37 EDTAMTDTD Ameritrade shares look vulnerable in the near-term, Barron's says
Subscribe for More Information
May 15, 2015
14:51 EDTMYLMylan ANDA for generic version of Lexapro approved by FDA
The ANDA from Mylan (MYL) for a generic version of Escitalopram Oxalate, which is sold under the trade name Lexapro by Actavis' (ACT) Forest Labs, was approved by the FDA on May 14, according to a post to the regulator's site. Reference Link
09:31 EDTMYLAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
08:06 EDTETFCE-Trade reports April DARTs 157,442, down 1% from March
E*TRADE Financial Corporation released its Monthly Activity Report for April 2015. Daily Average Revenue Trades for April were 157,442, a one percent decrease from March and an eight percent decrease from the year-ago period. The Company added 37,077 gross new brokerage accounts in April, ending the month with approximately 3.2 million brokerage accounts — an increase of 8,315 from March. Net new brokerage assets were negative $0.4B in the month. During the month, customer security holdings increased by one percent, or $3.1B, and brokerage-related cash decreased by $0.3B to $41.3B. Bank-related cash and deposits decreased by $0.3B, ending the month at $5.5B. Customers were net sellers of approximately $0.5B in securities during the month.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use